

# Denis Migliorini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7253158/publications.pdf>

Version: 2024-02-01

34  
papers

2,070  
citations

471061

17  
h-index

344852

36  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3084  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical relevance of tumour-associated macrophages. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 402-421.	12.5	250
2	The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. <i>Cell Metabolism</i> , 2022, 34, 731-746.e9.	7.2	63
3	Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread. <i>Neurology: Genetics</i> , 2021, 7, e561.	0.9	1
4	Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3493.	1.8	4
5	Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 640082.	2.2	64
6	Fitness-to-drive for glioblastoma patients. <i>Swiss Medical Weekly</i> , 2021, 151, w20501.	0.8	3
7	MXV-ONCO-1 in advanced refractory cancers: Safety, feasibility, and preliminary efficacy results from all HNSCC patients treated in two ongoing clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18005-e18005.	0.8	5
8	Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells. <i>Human Gene Therapy</i> , 2021, 32, 1044-1058.	1.4	35
9	From Focused Ultrasound Tumor Ablation to Brain Blood Barrier Opening for High Grade Glioma: A Systematic Review. <i>Cancers</i> , 2021, 13, 5614.	1.7	8
10	Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7449.	1.8	19
11	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. <i>Cell</i> , 2020, 183, 126-142.e17.	13.5	269
12	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. <i>Biology</i> , 2020, 9, 264.	1.3	7
13	Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 89.	1.3	14
14	Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients. <i>Cancers</i> , 2019, 11, 464.	1.7	19
15	Phase I/II trial testing safety and immunogenicity of the multi-peptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. <i>Neuro-Oncology</i> , 2019, 21, 923-933.	0.6	89
16	Current strategies for vaccination in glioblastoma. <i>Current Opinion in Oncology</i> , 2019, 31, 514-521.	1.1	4
17	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
18	Glycan-directed CAR-T cells. <i>Glycobiology</i> , 2018, 28, 656-669.	1.3	74

#	ARTICLE	IF	CITATIONS
19	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. <i>Oncolimmunology</i> , 2018, 7, e1391972.	2.1	42
20	CAR T-Cell Therapies in Glioblastoma: A First Look. <i>Clinical Cancer Research</i> , 2018, 24, 535-540.	3.2	103
21	Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development. <i>ILAR Journal</i> , 2018, 59, 276-285.	1.8	5
22	Checkpoint Blockade Reverses Anergy in IL-13R $\alpha$ 2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 20-38.	2.0	123
23	BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma. <i>Neurology</i> , 2017, 88, 1291-1293.	1.5	41
24	First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. <i>Oncolimmunology</i> , 2017, 6, e1338235.	2.1	52
25	Rapidly Growing Pulmonary Metastasis from Anaplastic Meningioma with Lethal Outcome: A Case Report. <i>Journal of Neurological Surgery Reports</i> , 2017, 78, e129-e134.	0.3	8
26	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	1.3	39
27	ATIM-21. IMA950 PEPTIDE-BASED VACCINE ADJUVANTED WITH POLY-ICLC IN COMBINATION WITH STANDARD THERAPY IN NEWLY DIAGNOSED HLA-A2 GLIOBLASTOMA PATIENTS: PRELIMINARY RESULTS. <i>Neuro-Oncology</i> , 2016, 18, vi22-vi22.	0.6	5
28	Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?. <i>CNS Oncology</i> , 2016, 5, 199-201.	1.2	1
29	MXV-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology. <i>Annals of Oncology</i> , 2016, 27, vi362.	0.6	10
30	Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. <i>Journal of Neuro-Oncology</i> , 2016, 126, 175-183.	1.4	18
31	Immunotherapy of Brain Tumors. <i>Progress in Tumor Research</i> , 2015, 42, 11-21.	0.1	7
32	The CD40/CD40L axis in glioma progression and therapy. <i>Neuro-Oncology</i> , 2015, 17, 1428-1430.	0.6	12
33	Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. <i>CNS Oncology</i> , 2015, 4, 387-392.	1.2	28
34	Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies. <i>Immunotherapy</i> , 2013, 5, 1147-1150.	1.0	2